It-hMSC is under clinical development by Stemedica Cell Technologies and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II drugs for Dermatological Disorders have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how It-hMSC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

It-hMSC overview

Stem cell therapy (Stemedyne-MSC) is under development for the treatment of non-ischemic heart failure, post-acute sequelae of COVID 2019 (PASC or Long COVID), ischemic stroke, chronic heart failure, traumatic brain injury and Alzheimer's disease.The therapy is administered through intravenous route. Mesenchymal stem cells (MSCs) are multipotent stem cells found in bone marrow. It was also under development for the treatment of acute lung injury, bacterial sepsis, acute myocardial infarction, diabetic retinopathy and ageing, cutaneous radiation toxicity and dermatological disorders.

It was under development for the treatment of peripheral arterial disease.

Stemedica Cell Technologies overview

Stemedica Cell Technologies (Stemedica) is a Biotechnology company. It offers regenerative medicine, healthcare products. The company manufactures and develops adult ischemic tolerant stem cells and stem cell derived factors. It provides allogeneic adult stem cell products such as mesenchymal stem cells derived from adult bone marrow, neural stem cells obtained from donated brain tissue and retinal epithelial cells. Stemedica’s products are used in clinical trials for the treatment of cardiac, ophthalmological, alzheimer’s, ischemic stroke, neurological, and dermatological indications. The company operates through universities and research institutions to advance adult stem cell treatments through translational medicine. It operates in the US and Switzerland. Stemedica is headquartered in San Diego, California, the US.

For a complete picture of It-hMSC’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.